CAR T-Cell Therapy a ‘Really Exciting’ Development in Treatment of Lymphomas – Curetoday.com
Posted: May 22, 2020 at 2:51 pm
The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.
BY Dr. Ian Flinn
The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.
In an interview with CURE, Flinn, the director of lymphoma research at Sarah Cannon Research Institute, discussed the use of CAR T-cells to treat lymphomas, as well as how the ZUMA-2 trial is shaping up to influence the treatment of patients with mantle cell lymphoma.
Transcription:
CURE: I'm curious about the ZUMA-2 trial. I know that you're an investigator on that trial. So, if you could talk a little bit about the drug, what it targets, how it works in the body and where things are with that study so far.
Flinn: ZUMA-2 is a clinical trial looking at a CAR T-cell product that targets CD19, which is an antigen on a lot of lymphomas, in this case mantle cell lymphoma, in patients who have had multiple prior therapies for their mantle cell lymphoma, and who are really no longer responding.
So, in this trial, we administered CAR T-cells to these patients. And after giving them some what's called lymphodepleting chemotherapy, and then infuse the CAR T-cells into the patients, we saw a really pretty remarkable outcome.
First (let me offer) a little bit about what a CAR T-cell is. Its a white blood cell, a lymphocyte, that is harvested from the blood of a patient. It's then sent to a central manufacturing facility, where a gene is inserted into the lymphocyte to have the lymphocyte activate as well as target the lymphoma. In this case, it's targeting that antigen called CD19, that's present on most B cell lymphomas and most all the mantle cell lymphoma, many other types of lymphoma as well.
So, it's a really exciting development in the treatment of all lymphomas and in certain forms of leukemia. A similar CAR T-cell product had previously been shown to be very effective in patients with an aggressive form of lymphoma, known as large cell lymphoma. And studies in that patient population led to the approval of CAR T-cells for patients with diffuse large B-cell lymphoma, who also similarly were not really responding to any agents anymore. The therapy had really run the course of what conventional treatments (could offer). And in that patient population there was about a 40%, what looks like long term cure rate for that patient population, so really fabulous results in large cell lymphoma.
And so, in this trial, this trial ZUMA-2, we're hoping to see similar activity in patients with, again, very difficult-to-treat mantle cell lymphoma, patients who already had standard of care therapies such as a tyrosine kinase inhibitor, and chemo immunotherapy. And we saw very remarkable results. Two-thirds of patients achieved a complete remission in this study, and the follow up is relatively short, but in a subgroup of patients that have been followed for more than two years on, about 40% of patients remain in remission.
So, this would be the first CAR T-cell product that will be available to patients with mantle cell lymphoma?
Right. This would be the first CAR T-cell product that's available for mantle cell lymphoma patients. We hope to see FDA approval sometime this summer. It's been submitted to the FDA for approval, and they have certain timelines that the FDA has to make. And based on that, we know that we should hear the latest by August on whether this drug will be approved.
Is there anything else that people should know about this particular study?
I think the other thing to know is when anybody is looking at any kind of therapy, is what are the risks and benefits of this? It sounds wonderful, augmenting the immune system and you're harnessing the immune system to fight the cancer, which is really what this is doing. But it does have side effects. And, and those side effects are sometimes scary.
There's something called cytokine release syndrome, where basically as I explain it to patients, it's like someone's getting the worst flu of their life. I mean, sometimes they can have fevers as high as 104 (degrees). But when you think about it, that's kind of what we're wanting. We want the immune system to be turned on. We want it to go after this lymphoma, what it thinks is foreign. (But) then we've learned better ways of decreasing those side effects now by using other medications to decrease the incidence and severity of cytokine release syndrome.
The other toxicity is called neurological toxicity, or neurotoxicity, and this can be very disturbing to patients and their family members. Because it can sometimes range from just being a little bit sleepy to people being in a full coma. Luckily, nobody died in this study from this, and we're getting better at intervening earlier to decrease the severity of neurologic toxicity. And so, for the vast majority of patients, it's reversible, but it's definitely something for patients who are considering this (drug) to talk to their doctor about.
Read more here:
CAR T-Cell Therapy a 'Really Exciting' Development in Treatment of Lymphomas - Curetoday.com
- Last Call with Jenna Balestrini, the WPI grad treating cancer with cell therapy - Worcester Mag - January 14th, 2021
- Province gives family facing $2.8M drug bill a glimmer of hope - CBC.ca - January 14th, 2021
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- This 6-year-old Iowa boy is losing his vision and hearing. But his family holds on to hope. - The Gazette - December 22nd, 2020
- What Is Gene Therapy? How Does It Work? | FDA - December 17th, 2020
- What is gene therapy? - The Star Online - December 17th, 2020
- What It's Like Rising A Little Boy With Advanced Breast Cancer - Oprah Mag - December 17th, 2020
- EAPM Advancing gene therapy with Advanced Therapy Medicinal Products - EU Reporter - December 16th, 2020
- San Diego's Locanabio raises $100 million for treatments aimed at degenerative diseases - The San Diego Union-Tribune - December 16th, 2020
- Italy needs new restrictions to avoid third, devastating COVID-19 wave - PM to paper - EU Reporter - December 16th, 2020
- Yes, men can get breast cancer here are the symptoms to watch for - Insider - INSIDER - December 12th, 2020
- Mumbai: Baby with genetic disorder needs Rs 16 crore therapy to live - Mid-day - December 12th, 2020
- Gene Therapy Liberates Hemophilia B Patients from Requiring Regular Infusions of Clotting Factor - MedicalResearch.com - December 12th, 2020
- Vaccination in the Era of Covid - Touro College News - December 7th, 2020
- Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic... - December 7th, 2020
- Medicare and cystic fibrosis: Coverage, options, treatments, and costs - Medical News Today - December 7th, 2020
- The FDA has approved the first drug to treat the rapid-aging disease progeria - Science News - November 26th, 2020
- 'This is why I'm here': A Detroit Lions VP tries to save her daughter from rare disease - ESPN - November 24th, 2020
- Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG - OncoZine - November 24th, 2020
- SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders - Business Wire - November 24th, 2020
- SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders - BioSpace - November 23rd, 2020
- Rare Mutation in the PCSK9 Gene Confers Long Healthy Life - MedicalResearch.com - November 23rd, 2020
- Living through the second wave - Pakistan Today - November 23rd, 2020
- How two blind brothers became Two Blind Brothers for a cause - The Columbian - November 10th, 2020
- How two blind brothers created a one-of-a-kind shopping experience to raise money for a cure - WXII The Triad - November 10th, 2020
- The ethical way to alter organisms - The Boston Globe - November 10th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 10th, 2020
- Medical Milestone In Boston: 13-Year-Old Gets New Gene ... - November 5th, 2020
- How immunotherapy is revolutionizing cancer care - Genetic Literacy Project - October 29th, 2020
- The good news about breast cancer - The Gazette - October 29th, 2020
- Harris County parents win insurance appeal for 8-year-olds MD treatment - WRBL - October 29th, 2020
- Biohack the ageing process by taking care of this little protein in your body - Lifestyle Asia - October 22nd, 2020
- 'I have faith and I prayed a lot' - News from southeastern Connecticut - theday.com - October 22nd, 2020
- Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation - Breastcancer.org - October 20th, 2020
- Beating Cancer: Prevention must be 'cornerstone' of EU's new approach - The Parliament Magazine - October 20th, 2020
- Watch: New 5-minute injection a game-changer in breast cancer therapy in UAE - Gulf News - October 20th, 2020
- Homer Glen Mom and Nurse Breast Cancer-Free after Radiation Therapy Clinical Trial at UChicago Medicine Comprehensive Cancer Center at Silver Cross -... - October 20th, 2020
- Teenager among first to receive gene therapy treatment for rare condition - KRDO - October 8th, 2020
- Proposition 14: With Just Handful of Cures, California Stem Cell Agency's Fate Is In Hands of Voters - KQED - October 8th, 2020
- Teenager among first to receive gene therapy treatment for rare condition - NewsChannel 3-12 - KEYT - October 7th, 2020
- Greenbrier County teen to be among first in nation to receive gene therapy for Hurler's Syndrome - WVVA TV - October 7th, 2020
- Regenxbio RGX-121 Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha - October 7th, 2020
- Women In Longevity Medicine And The Rise Of The Longevity Physician - Forbes - October 7th, 2020
- Timothy Ray Brown, First Patient to Be Cured of HIV, Dies of Leukemia - BioSpace - October 7th, 2020
- Different Types of Childhood Cancer | INTEGRIS - Integris - October 4th, 2020
- Gene therapy company Taysha completes sprint from first funding to IPO - BioPharma Dive - September 26th, 2020
- Focused on the future: Innovative college programs in N.J. pave way for the real world - Jersey's Best - September 24th, 2020
- Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH - Medscape - September 22nd, 2020
- 10 Forgotten Spiderman Sidekicks They Need To Bring Back | CBR - CBR - Comic Book Resources - September 22nd, 2020
- Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020 - Business... - September 21st, 2020
- BCS Announces Partnership With 2nd.MD to Improve Member Healthcare Cost, Quality, and Outcomes - PRNewswire - September 19th, 2020
- Novus Therapeutics Announces Acquisition of Anelixis Therapeutics - Business Wire - September 19th, 2020
- Pace toddler wasn't supposed to survive. Thanks to wonder drug, parents say he's thriving - Pensacola News Journal - September 8th, 2020
- CRISPR can help combat the troubling immune response against gene therapy - The Conversation US - September 6th, 2020
- How Is Ovarian Cancer Diagnosed? Everything You Need To Know - NDTV Doctor - September 6th, 2020
- Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |... - September 6th, 2020
- Gilmore Health: A Q&A Session on Genetic Diseases With Dr. Sony Sherpa - Gilmore Health News - September 6th, 2020
- Our teenage son is turning to stone and is becoming entombed in his own body - The Sun - August 28th, 2020
- Gene Therapy: IT Meets Medicine, But Who Is In Charge? - Walter Bradley Center for Natural and Artificial Intelligence - August 24th, 2020
- Edited Transcript of ISEE.OQ earnings conference call or presentation 5-Aug-20 12:00pm GMT - Yahoo Finance - August 6th, 2020
- Opinion: With any COVID-19 vaccine, humanity will face its biggest moral test - The Province - August 4th, 2020
- These Companies Are Seeking a Cure for Sickle Cell. And Its Just the Beginning for Some Gene Therapy Stocks. - Barron's - July 31st, 2020
- FDA Approves Combination Therapy for Treating Advanced Melanoma - Pharmacy Times - July 31st, 2020
- How Can Technology Help Fight the COVID-19 Pandemic? - IoT For All - July 31st, 2020
- Thomas Jefferson University doctor to be honored at W&J commencement - Observer-Reporter - July 30th, 2020
- First Edition: July 27, 2020 - Kaiser Health News - July 30th, 2020
- These are the most valued tech startups in France in 2020 - Silicon Canals - July 7th, 2020
- What's a life worth in dollars and cents? Should that influence who gets treated for expensive disease treatments? - Genetic Literacy Project - July 1st, 2020
- FDA Approves Genentech's Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer -... - July 1st, 2020
- Conversations Between Patient and Oncologist Are Important in Avoiding 'Common Mistake' When Treating CLL - Curetoday.com - June 28th, 2020
- Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma - The Institute of Cancer Research - June 28th, 2020
- Family Of Dying Santa Clarita Teen Pleads With Community For Donations To Fund Life-Saving Treatment - KHTS Radio - June 24th, 2020
- Hungarian Neurobiologist Botond Roska to Receive This Year's Krber European Science Prize - Hungary Today - June 24th, 2020
- Quarterly summary: the COVID-19 lockdown and the importance of scientists - University Affairs - June 24th, 2020
- Flames assistant GM continues to defy the odds in his battle against ALS - CTV News - June 23rd, 2020
- 3 Reasons to Go Long Crispr Therapeutics - InvestorPlace - June 23rd, 2020
- GRIN Disorder, Kidney Failure and Fathers Day How One Family is Surviving it All - CBC.ca - June 23rd, 2020
- Gene Therapy: Regal Profits From Curing "The Royal Disease"? - Sick Economics - June 18th, 2020
- Cancer patients and doctors carry on with clinical trials during Covid-19 - STAT - June 18th, 2020
- Genentech's Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response,... - June 18th, 2020